During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
The following is a guest post by Jacqueline Hellen and Lisa Parker of MEASURE Evaluation While programs in low- and middle-income countries seek to support children […]